comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 18:23:08 - browse：74145

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： FDA's Pazdur wants cancer trials to range beyond China alone

WSS

With trial win, GSK could get blood cancer drug back on market

NIH documents show early flaws of $1.6 billion long Covid program

At ASCO, AstraZeneca reports strong data for breast cancer drug

Pennsylvania man bitten on the head by bear during attack in his garage

'Brian's Song' at 50 still offers lessons about cancer for today

Feed a cold, starve a fever? Here’s what science says

leisure time

comprehensive

entertainment

At least 13 dead in Texas as scorching temps continue

Tuberculosis patients need more than just free medication

Activists slam private health insurers over coverage restrictions

Shifting the focus from loneliness to social health

Affirmative action in medical school literally saved lives

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

What does generative AI mean for health care? We asked experts

Election results set back Medicaid expansion plans

At least 13 dead in Texas as scorching temps continue

It was time to plan for my old age. If only I could stop crying

focus

Slovenia has suffered its worst

BMI, flaws aside, is found to be useful estimate of body fat in youth

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

Change Healthcare can notify patients about the breach, HHS says

It was time to plan for my old age. If only I could stop crying

How CRISPR works, explained in two minutes

knowledge

Wikipedia

knowledge

knowledge